Comparative Pharmacology
Head-to-head clinical analysis: EPRONTIA versus LACOSAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPRONTIA versus LACOSAMIDE.
EPRONTIA vs LACOSAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by inhibiting presynaptic serotonin reuptake.
Selectively enhances slow inactivation of voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes and inhibiting repetitive neuronal firing.
Adults: 200-800 mg twice daily orally, starting at 200 mg twice daily, increasing by 200 mg/day weekly to maintenance.
Oral or IV: 50 mg twice daily initially; increase by 50 mg twice daily weekly to maintenance 100-200 mg twice daily. Maximum 200 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is 20–30 hours in adults with normal renal function; prolonged to 40–60 hours in moderate to severe renal impairment (CrCl <50 mL/min), requiring dose adjustment.
Clinical Note
moderateLacosamide + Sulfisoxazole
"The serum concentration of Sulfisoxazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Fluconazole
"The serum concentration of Fluconazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Ketoconazole
"The serum concentration of Ketoconazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Delavirdine
Terminal elimination half-life is approximately 13 hours (range 12–16 hours) in adults. Steady state achieved after 3 days with BID dosing.
Renal excretion of unchanged drug accounts for approximately 70% of elimination, with 30% metabolized hepatically; metabolites are also renally excreted. Fecal elimination is minimal (<5%).
Renal: approximately 95% (40% unchanged, remainder as O-desmethyl metabolite). Fecal: <5%.
Category C
Category C
Anticonvulsant
Anticonvulsant
"The serum concentration of Delavirdine can be increased when it is combined with Lacosamide."